X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (21) 21
index medicus (19) 19
pharmacokinetics (18) 18
female (17) 17
rilpivirine (17) 17
male (16) 16
pharmacology & pharmacy (16) 16
adult (15) 15
safety (13) 13
middle aged (12) 12
pyrimidines - adverse effects (12) 12
human immunodeficiency virus--hiv (11) 11
nitriles - adverse effects (11) 11
pyrimidines - administration & dosage (11) 11
antiretroviral drugs (10) 10
nitriles - administration & dosage (10) 10
efavirenz (9) 9
infectious diseases (9) 9
young adult (9) 9
adolescent (8) 8
anti-hiv agents - administration & dosage (8) 8
drug interactions (8) 8
efficacy (8) 8
hiv (8) 8
hiv infections - drug therapy (8) 8
pyrimidines - pharmacokinetics (8) 8
treatment outcome (8) 8
anti-hiv agents - adverse effects (7) 7
emtricitabine (7) 7
etravirine (7) 7
immunology (7) 7
nitriles - pharmacokinetics (7) 7
pharmacology (7) 7
hiv-1 (6) 6
animals (5) 5
anti-hiv agents - pharmacology (5) 5
antiretroviral therapy (5) 5
benzoxazines - administration & dosage (5) 5
clinical trials (5) 5
hiv reverse transcriptase - antagonists & inhibitors (5) 5
hiv-1 - drug effects (5) 5
internal medicine (5) 5
phase-3 (5) 5
research (5) 5
reverse transcriptase inhibitors - pharmacokinetics (5) 5
tenofovir (5) 5
tmc278 (5) 5
aged (4) 4
aids/hiv (4) 4
anti-hiv agents - therapeutic use (4) 4
antiviral agents (4) 4
atherosclerosis (4) 4
benzoxazines - adverse effects (4) 4
darunavir (4) 4
dosage and administration (4) 4
double-blind (4) 4
drug administration schedule (4) 4
hiv infections - virology (4) 4
mice (4) 4
mice, inbred c57bl (4) 4
nitriles - pharmacology (4) 4
non-nucleoside reverse transcriptase inhibitor (4) 4
pyridazines - pharmacokinetics (4) 4
pyrimidines - pharmacology (4) 4
reverse transcriptase inhibitors - administration & dosage (4) 4
therapy (4) 4
trial (4) 4
virology (4) 4
abridged index medicus (3) 3
adults (3) 3
anti-hiv agents - pharmacokinetics (3) 3
area under curve (3) 3
bioavailability (3) 3
combination (3) 3
cross-over studies (3) 3
dose-response relationship, drug (3) 3
double-blind method (3) 3
drug dosages (3) 3
drug therapy (3) 3
drug therapy, combination (3) 3
healthy volunteers (3) 3
injections, intramuscular (3) 3
medicine & public health (3) 3
medicine, general & internal (3) 3
metabolism (3) 3
mutation (3) 3
nitriles - therapeutic use (3) 3
nucleotides (3) 3
pregnancy (3) 3
pyrimidines - blood (3) 3
pyrimidines - therapeutic use (3) 3
reverse transcriptase inhibitors - adverse effects (3) 3
reverse transcriptase inhibitors - pharmacology (3) 3
thrive (3) 3
usage (3) 3
abstract supplement (2) 2
acquired immune deficiency syndrome--aids (2) 2
acquired immunodeficiency syndrome - drug therapy (2) 2
acquired immunodeficiency syndrome - ethnology (2) 2
acquired immunodeficiency syndrome - virology (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9787, pp. 238 - 246
Summary Background Efavirenz with tenofovir-disoproxil-fumarate and emtricitabine is a preferred antiretroviral regimen for treatment-naive patients infected... 
Internal Medicine | LAMIVUDINE | MEDICINE, GENERAL & INTERNAL | EFFICACY | SAFETY | COMBINATION THERAPY | GUIDELINES | PROTEASE-INHIBITOR | ANTIRETROVIRAL THERAPY | NEVIRAPINE | REGIMENS | Rilpivirine | HIV Reverse Transcriptase - antagonists & inhibitors | Humans | Middle Aged | Male | Anti-HIV Agents - administration & dosage | Nitriles - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Adenine - adverse effects | Adenine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Reverse Transcriptase Inhibitors - therapeutic use | Acquired Immunodeficiency Syndrome - virology | Acquired Immunodeficiency Syndrome - ethnology | Emtricitabine | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Double-Blind Method | Drug Administration Schedule | Organophosphonates - therapeutic use | HIV-1 - drug effects | Pyrimidines - administration & dosage | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | Organophosphonates - adverse effects | Benzoxazines - adverse effects | Treatment Outcome | HIV-1 - genetics | Acquired Immunodeficiency Syndrome - drug therapy | Adenine - administration & dosage | Benzoxazines - therapeutic use | Organophosphonates - administration & dosage | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Aged | Mutation | Nitriles - adverse effects | Viral Load - drug effects | Deoxycytidine - analogs & derivatives | Nitriles - therapeutic use | Dosage and administration | Efavirenz | Patient outcomes | Clinical trials | Antiretroviral drugs | Drug therapy | Human immunodeficiency virus--HIV
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9787, pp. 229 - 237
Summary Background The non-nucleoside reverse transcriptase inhibitor (NNRTI), rilpivirine (TMC278; Tibotec Pharmaceuticals, County Cork, Ireland), had... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | ZIDOVUDINE | COMBINATION THERAPY | ACTIVE ANTIRETROVIRAL THERAPY | EMTRICITABINE | PROTEASE-INHIBITOR | CYSTATIN-C | CREATININE | DAILY LAMIVUDINE | NEVIRAPINE | TENOFOVIR | Rilpivirine | HIV Reverse Transcriptase - antagonists & inhibitors | Humans | Middle Aged | Male | Anti-HIV Agents - administration & dosage | Nitriles - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Nucleotides - therapeutic use | Adenine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Reverse Transcriptase Inhibitors - therapeutic use | Acquired Immunodeficiency Syndrome - virology | Acquired Immunodeficiency Syndrome - ethnology | Emtricitabine | Nucleosides - therapeutic use | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Double-Blind Method | Drug Administration Schedule | Organophosphonates - therapeutic use | HIV-1 - drug effects | Pyrimidines - administration & dosage | Anti-HIV Agents - adverse effects | Benzoxazines - adverse effects | Treatment Outcome | HIV-1 - genetics | Acquired Immunodeficiency Syndrome - drug therapy | Benzoxazines - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Mutation | Nitriles - adverse effects | Viral Load - drug effects | Deoxycytidine - analogs & derivatives | Nitriles - therapeutic use | Evaluation | Patient outcomes | Clinical trials | Dosage and administration | Drug therapy | HIV infection | Design | Antiretroviral drugs | Corporate sponsorship | Human immunodeficiency virus--HIV | Technological change | Research | Clinical medicine | Drugs | RNA-directed DNA polymerase | Exanthema | antiretroviral therapy | Lamivudine | Lipids | Nucleotides | Regression analysis | Efavirenz | CD4 antigen | nucleosides | Algorithms | Hospitals | non-nucleoside reverse transcriptase inhibitors | Abacavir | Zidovudine | Pharmaceuticals
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 08/2013, Volume 53, Issue 8, pp. 834 - 840
Journal Article
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 09/2014, Volume 54, Issue 9, pp. 1048 - 1057
Journal Article
AIDS, ISSN 0269-9370, 03/2013, Volume 27, Issue 6, pp. 939 - 950
Journal Article
JAIDS Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 05/2012, Volume 60, Issue 1, pp. 33 - 42
Journal Article
Journal Article
Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 11/2016, Volume 73, Issue 3, p. 268
  Background: Treatment of HIV-1-infected women during pregnancy protects maternal health and reduces the risk of perinatal transmission of HIV-1. However,... 
Pregnancy | Antiretroviral drugs | Disease transmission | Maternal & child health | Human immunodeficiency virus--HIV | Reaction kinetics | Pharmacology
Journal Article
JAIDS Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 11/2016, Volume 73, Issue 3, pp. 268 - 268
Background: Treatment of HIV-1-infected women during pregnancy protects maternal health and reduces the risk of perinatal transmission of HIV-1. However,... 
Journal Article
Infectious Diseases and Therapy, ISSN 2193-8229, 3/2018, Volume 7, Issue 1, pp. 147 - 159
Physiologic changes during pregnancy may impact the pharmacokinetics of drugs. In addition, efficacy and safety/tolerability concerns have been identified for... 
Pregnancy | Medicine & Public Health | HIV | Rilpivirine | Internal Medicine | Infectious Diseases | Pharmacokinetics | Antiretroviral drugs | Human immunodeficiency virus--HIV | Patient safety | Clinical trials | Pharmacology | Clinical outcomes | Original Research
Journal Article
17.